Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Ophthalmic Drug Delivery Systems

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ocular toxoplasmosis in Latin American and European patients: clinical characteristics, visual outcomes, and recurrence patterns.

Journal of ophthalmic inflammation and infection·2026

Same author

Analysis of Histostructural Modifications in the Ocular Surface of Patients With Chronic Glaucoma.

Investigative ophthalmology & visual science·2026

Same author

Vascular endothelial growth factor inhibitors outcomes in good vision eyes with neovascular age-related macular degeneration: Fight Retinal Blindness! SPAIN Report 4.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026

Same author

The role of interleukin-6 in diabetic retinal disease: pathophysiology and therapeutic targeting.

Frontiers in immunology·2026

Same author

Ultra-widefield retinal imaging for early detection of asymptomatic cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation: a prospective pilot feasibility study.

Journal of ophthalmic inflammation and infection·2026

Same author

Decellularized Aged Bruch's Membrane Confers Unique Biochemical Cues to Retinal Pigment Epithelium for In Vitro Modeling of Age-Related Macular Degeneration.

Aging cell·2026

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

Oxaliplatin-Related Ocular Toxicity.

Marina Mesquida¹, Bernardo Sanchez-Dalmau, Santiago Ortiz-Perez

¹Ophthalmology Department, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.

Case Reports in Oncology

|December 15, 2010

Summary

Oxaliplatin chemotherapy for colorectal cancer can cause vision loss and neurological issues. This case highlights potential permanent retinal pigment epithelium damage, differing from typical reversible side effects.

More Related Videos

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

Related Experiment Videos

Last Updated: Jun 6, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

Area of Science:

Oncology
Ophthalmology
Neuroscience

Background:

Oxaliplatin is a common chemotherapy agent used in treating advanced colorectal cancer, often administered on a FOLFOX regimen.
Ocular toxicity is a known, though infrequent, adverse event associated with oxaliplatin treatment.

Observation:

A 52-year-old woman receiving oxaliplatin developed progressive visual loss, altered color vision, and neurological symptoms after three cycles.
Ophthalmological examination revealed bilateral concentric visual field defects and electrooculogram abnormalities indicating severe retinal pigment epithelium impairment.

Findings:

The case suggests oxaliplatin can induce toxicity specifically targeting the retinal pigment epithelium, a manifestation not previously documented.
While visual acuity and visual fields recovered within eight months, electrooculogram results remained abnormal, suggesting potentially permanent retinal damage.

Implications:

This finding expands the known spectrum of oxaliplatin-induced ocular toxicities, indicating a possible non-transient form of retinal damage.
Awareness of this specific retinal pigment epithelium toxicity is crucial for clinicians managing colorectal cancer patients undergoing oxaliplatin therapy.